Table 2.

Summary of adjusted (anova) mean pharmacokinetic parameters for ziprasidone on days 5 and 13 during placebo and ketoconazole administration.

	Ziprasidone + placebo (n =13)	Ziprasidone + ketoconazole (n =13)	Ratio (AUC and Cmax) or difference (tmax, λz)	95% CI	Pd (T effect)
AUC(0,∞)a(ng ml−1 h)	899	1199	133.3%	112.4–158.1%	0.003
Cmaxa (ng ml−1)	89	119	133.5%	106.9–166.7%	0.015
tmaxb (h)	8.5	9.2	0.7	−1.7–3.0	0.549
λzb (h−1)	0.164	0.183	0.019	−0.012–0.051	0.197
t½,zc (h)	4.2	3.8	0.45	–	–

^aAdjusted geometric mean.

^bAdjusted arithmetic mean.

^cCalculated as ln 2/mean λ_z.

^dSignificance for treatment (T) effect.